Abstract
The treatment of Chagas disease (CD), a neglected parasitic condition caused by Trypanosoma cruzi, is still based on only two drugs, nifurtimox (Nif) and benznidazole (Bz), both of which have limited efficacy in the late chronic phase and induce severe side effects. This scenario justifies the continuous search for alternative drugs, and in this context, the natural naphthoquinone β-lapachone (β-Lap) and its derivatives have demonstrated important trypanocidal activities. Unfortunately, the decrease in trypanocidal activity in the blood, high toxicity to mammalian cells and low water solubility of β-Lap limit its systemic administration and, consequently, clinical applications. For this reason, carriers as drug delivery systems can strategically maximize the therapeutic effects of this drug, overcoming the above mentioned restrictions. Accordingly, the aim of this study is to investigate the in vitro anti-T. cruzi effects of β-Lap encapsulated in2-hydroxypropyl-β-cyclodextrin (2HP-β-CD) and its potential toxicity to mammalian cells.
Funder
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Fundação Oswaldo Cruz
Print Fiocruz-Capes
Publisher
Public Library of Science (PLoS)
Reference63 articles.
1. World Health Organization, Chagas disease. 2020; Available from: https://www.who.int/health-topics/chagas-disease#tab=tab_1.
2. Chagas disease;A Rassi;Lancet,2010
3. World Health Organization Chagas disease in Latin America: an epidemiological update based on 2010 estimates;Week Epidemiol Rec,2015
4. A critical review on Chagas disease chemotherapy;JR Coura;Mem Inst Oswaldo Cruz,2002
5. Chagas disease. What is known and what should be improved: a systemic review;JR Coura;Rev Soc Bras Med Trop,2012
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献